Skip to main content

Trovagene Q3 Revenues Increase as It Nears Test Launch

NEW YORK (GenomeWeb News) – Trovagene today reported that its third-quarter revenues climbed to $211,000 from $55,000, as the firm nears the launch of its first molecular diagnostic tests.

The San Diego-based firm said that it received a milestone payment of $150,000 during the quarter. It said in August that had achieved an intellectual property milestone under its license agreement with Qiagen subsidiary Ipsogen, triggered by the issuance of a US patent cover the diagnostic use of nucleophosmin protein mutations in patients with acute myeloid leukemia.

It posted a net loss of $650,000, or $.05 per share, for the three months ended Sept. 20, compared to a profit of $9,000, or $.00 per share, for Q3 2011. The third quarter of 2011 included a gain of $623,000 from extinguishment of debt.

Trovagene's R&D spending more than doubled to $511,000 from $201,000, and its general and administrative costs increased to $739,000 from $586,000.

"We are on track to offer our first molecular diagnostic test for the detection of oncogene mutations in the urine of cancer patients as well as a proprietary urine-based HPV test by the end of the year," Trovagene CEO Antonius Schuh said in a statement.

During the quarter, Trovagene licensed to Quest Diagnostics non-exclusive rights to incorporate the nucleophosmin protein (NPM1) into its research and testing services for acute myelogenous leukemia. It also has a deal with Strand Life Sciences to validate and offer its HPV assay in India and countries in the South Asian Association for Regional Cooperation.

Trovagene finished the third quarter with $7.8 million in cash and cash equivalents.

The Scan

Rise of B.1.617.2 in the UK

According to the Guardian, UK officials expect the B.1.617.2 variant to soon be the dominant version of SARS-CoV-2 there.

Anne Schuchat to Retire

Anne Schuchat is retiring after more than 30 years at the US Centers for Disease Control and Prevention, Politico reports.

US to Share More Vaccines

CNN reports that the US will share 20 million doses of the Moderna, Pfizer, and Johnson & Johnson SARS-CoV-2 vaccines with other countries.

PNAS Papers on Gene Therapy Platform, Aspergillus Metabolome, Undernutrition Model Microbiome

In PNAS this week: approach to deliver protein-based treatments to cells, pan-secondary metabolome of Aspergillus, and more.